Clinical Handbook of Psychotropic Drugs

Latest edition

New in this edition:

• Neuroscience-based nomenclature – added to product availability tables
• Antidepressants chapter includes new section on GABAA receptor positive modulator (brexanolone IV injection; trade name Zulresso)
• Also covers Qelbree (viloxazine extended-release capsules), the first new ADHD medication approved by the FDA in over a decade; as well as updates to SSRI use in pregnancy and antidepressant augmentation strategies
• Antipsychotics updates include revised dosing, especially adjustments in hepatic and renal impairment
• Mood stabilisers chapter sections on lithium and anticonvulsants extensively revised
• New formulations and trade names include: Adhansia XR (methylphenidate extended-release capsules), Caplyta (lumateperone), Dayvigo (lemborexant), Perseris (risperidone extended-release subcutaneous injection), Probuphine (buprenorphine subdermal implant), Propecia (finasteride tablets), Trelstar (triptorelin slow-release injection), Qelbree (viloxazine extended-release capsules), Zulresso (brexanolone IV injection)

Also available as online version – new features for subscribers

Subscribe now and get:

• Drug monographs: get all the relevant information about a single drug in a clear product monograph – with the option to display information about other drugs in the same class in addition
• Drug comparisons: compare drugs side by side, and see at a glance differences and similarities between them
• Enhanced responsive design: enjoy views and displays that are further optimized for ease of use on different devices (computers, tablets, smaller mobile devices), including a brand new, easy-to-read list view for comparison charts, fixed column and row headers in charts, and other improvements
• Full-text search: try out the new full-text search option, now available in addition to auto-completion searches for drug names, trade names, indications, and interacting agents

The Clinical Handbook of Psychotropic Drugs Online is the full-text online version of the popular Clinical Handbook of Psychotropic Drugs. As in the print edition, instantly recognizable icons and color coding allow you to find at a glance the information you seek. But the CHPD Online version offers much more. Unique features that allow even quicker access to the wealth of information include:

• Auto-completion powered search function
• Browse features for Generic Names, Trade Names, Indications, and Interacting Agents
• Hundreds of additional references
• Literature hot links for quick access to further reading

Clinical Handbook of Psychotropic Drugs for Children and Adolescents

Many psychotropic drugs are used to treat childhood and adolescent mental illness on the basis of efficacy in adults, despite not being currently approved for use in the young. The lack of approval does not necessarily reflect lack of safety or efficacy, but it does reflect a lack of controlled studies.

The Clinical Handbook of Psychotropic Drugs for Children and Adolescents is a unique resource to help you make the right choice for younger patients:

• Accurate and up-to-date
• Specific to children and adolescents
• Charts and tables help decision-making
• Icons and full color

Update of ADHD section of CHPD for Children and Adolescents Online

The update includes the selective norepinephrine reuptake inhibitor viloxazine (trade name Qelbree), a nonstimulant medication approved by the FDA in 2021 for the treatment of ADHD in children and adolescents aged 6–17, the first new ADHD treatment to be approved in over a decade. We have also added a Patient and Caregiver Information Sheet on viloxazine.
Further revisions include additional formulations of other treatments: Adhansia XR (methylphenidate extended-release capsules), Evekeo ODT (amphetamine orally disintegrating tablets), Jornay PM (methylphenidate delayed-release/extended-release capsules), and Vyvanse (lisdexamfetamine) chewable tablets.

The Clinical Handbook of Psychotropic Drugs for Children and Adolescents Online is the full-text online version of the popular Clinical Handbook of Psychotropic Drugs for Children and Adolescents. It retains all the practical features for which the Clinical Handbook is renowned and makes the information even more easily accessible.

As in the print edition, instantly recognizable icons and color coding allow you to find at a glance the information you seek. But the HPD for Children and Adolescents Online version offers much more. Unique features that allow even quicker access to the wealth of information include:

• Auto-completion powered search function
• Browse features for Generic Names, Trade Names, Indications, and Interacting Agents
• Column-selector enhancement of comparison charts that allows you to choose which information is displayed
• Hundreds of additional references
• Literature hot links for quick access to further reading

Free trial access

Get free trial access to CHPD Online and CHPD for Children & Adolescents Online for 14 days.

Free trial access codes:
For CHPD Online: 784e:1cd0:b4df:d4b3
For CHPD for Children & Adolescents Online: 623e:9da0:4b49:a866

Your trial access to each publication will be valid for 14 days from the time you redeem the code. Click here to see how it works.

If you have any questions or concerns, please don’t hesitate to contact our CHPD Online support.

Order information

Do you want print and online? Deal with adults and children? Then combine CHPD publications and save. The Clincial Handbook of Psychotropic Drugs is available as a print edition and as an online version, for adults and for children and adolescents. Each print edition and each online subscription (2 years) costs US $99.80.

• Buy any two CHPD products and save nearly US $50.
• Buy all four CHPD products and get 33% discount off the combined list prices!

Order now by clicking on the products that you want. The discount will be shown in your shopping cart during checkout.
Institutional customers, please contact chpd-online(at)hogrefe.com for subscription information.